Physician profile
Daniel Coffey
NPI 1760458293
$1,154.66
in general payments reported to CMS, 2019-2025
13 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $129 · 2022: $236 · 2023: $212 · 2024: $448 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $790.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $265.34 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $206.56 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $205.24 | 2024 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $199.57 | 2021-2025 | Nucala, Trelegy Ellipta |
| Genentech USA, INC. | $47.69 | 2024 | Xolair |
| Covis Pharma Gmbh | $43.58 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.37 | 2021-2024 | Glassia |
| Ars Pharmaceuticals Operations, INC. | $42.06 | 2025 | Neffy |
| Inspire Medical Systems, INC. | $32.86 | 2025 | Inspire |
| Kaleo, INC. | $24.13 | 2023 | Auvi-Q |
| Amgen INC. | $16.31 | 2022 | |
| Mylan Specialty L.P. | $15.85 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.10 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Coffey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.